PA
PAVM.US PAVmed Inc
- Market cap
- USD 13.0M
- P/E
- -
- P/B
- 0.41x
- ROE
- -89.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PAVM.US undervalued?
Graham numberThe Graham number of PAVmed Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PAVmed Inc fundamental analysis
No fundamental analysis for PAVmed Inc yet.
PAVmed Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PAVmed Inc
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection o…
Full company profilePAVmed Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PAVmed Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500K | 377K | 2.45M | 3.00M | 71.0K | 128K |
| Gross Profit | -3.79K | -7.11K | -9.79K | -14.2K | -23.0K | -85.0K | -3.24M | -3.97M | -3.04M | -252K | -401K |
| Operating Income | -5.65M | -8.03M | -10.6M | -14.3M | -23.4M | -54.4M | -91.1M | -68.8M | -44.5M | -21.8M | -29.0M |
| EBITDA | -5.65M | -11.2M | -12.1M | -16.7M | -23.3M | -55.9M | -99.5M | -75.7M | 29.7M | -2.34M | -19.1M |
| Net Income | -5.65M | -9.52M | -18.0M | -15.9M | -34.3M | -50.3M | -89.0M | -64.2M | 39.8M | 401K | -24.6M |
| EPS | -196 | -0.71 | -363 | -237 | -325 | -292 | -450 | -266 | 18 | 0.60 | -3.71 |
| Balance Sheet | |||||||||||
| Total Assets | 870K | 1.64M | 8.50M | 7.24M | 19.8M | 87.0M | 54.0M | 33.1M | 30.7M | 38.8M | 35.2M |
| Total Liabilities | 1.19M | 4.49M | 11.0M | 11.9M | 20.3M | 7.56M | 43.0M | 57.1M | 37.7M | 16.5M | 25.1M |
| Shareholders' Equity | -319K | -2.85M | -2.31M | -3.82M | 1.90M | 61.7M | -9.68M | -53.8M | -2.50M | 34.0M | 27.5M |
| Cash & Short-term Investments | 586K | 1.54M | 8.22M | 6.22M | 17.5M | 79.2M | 42.7M | 19.6M | 1.19M | 1.54M | 3.64M |
| Total Debt | - | 3.89M | 7.90M | 8.14M | 15.0M | - | 36.6M | 48.7M | 31.9M | 13.3M | 16.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.45M | -6.61M | -8.79M | -13.4M | -21.9M | -40.6M | -71.0M | -52.0M | -33.6M | -5.21M | -3.82M |
| Capital Expenditure | 21.8K | 5.30K | 26.6K | 27.2K | 55.0K | 1.47M | 1.54M | 242K | 55.0K | 31.0K | 93.3K |
| Free Cash Flow | -4.48M | -6.61M | -8.81M | -13.4M | -22.0M | -42.1M | -72.5M | -52.3M | -33.6M | -5.24M | -3.82M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -1,807.8% | -81.6% | - | - | - | 1.2% | -89.7% |
| ROA | -649.2% | -580.6% | -211.5% | -220.0% | -173.3% | -57.9% | -164.8% | -193.8% | 129.8% | 1.0% | -70.0% |
| Net Profit Margin | - | - | - | - | - | -10,069.4% | -23,602.9% | -2,617.3% | 1,328.6% | 564.8% | -19,249.0% |
| Debt to Equity | - | - | - | - | 7.89x | - | - | - | - | 0.39x | 0.58x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PAVmed Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 12.5B | 52,055 | - |
| 2022 | USD 35.2M | 178 | - |
| 2021 | USD 436M | 2,531 | - |
| 2020 | USD 357K | 3.39 | - |
| 2019 | USD 67.4B | 1,004,933 | - |
| 2018 | USD 7.10K | 0.14 | - |
| 2017 | USD 7.10K | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:30 on Jan 2, 2026.
Who owns PAVmed Inc
- Insiders 43.09%
- Institutions 26.17%
- Public & others 30.74%
- Shares outstanding 8.00M
- Free float 3.97M
Top funds holding PAVM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 20.8K | 0.26% | -34.58% | Sep 2026 |
| iShares Micro-Cap ETF | 12.0K | 0.15% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 3.01K | 0.04% | 0.00% | Aug 2026 |
| Fidelity Series Total Market Index | 2.36K | 0.03% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 881.00 | 0.01% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 877.00 | 0.01% | 0.00% | Sep 2026 |
| Guggenheim Active Allocation Fund | 2.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding PAVM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| First Manhattan Co. LLC | 333K | 4.16% | +1,298.49% | Jun 2026 |
| Vanguard Capital Management, LLC | 61.6K | 0.77% | +941.14% | Jun 2026 |
| Geode Capital Management, LLC | 36.7K | 0.46% | +211.44% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 25.6K | 0.32% | +371.63% | Jun 2026 |
| BlackRock Inc | 17.1K | 0.21% | +607.45% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 163.00 | 0.00% | -1.21% | Jun 2026 |
| Barclays PLC | 75.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 67.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 57.00 | 0.00% | -24.00% | Jun 2026 |
| Wells Fargo & Co | 45.00 | 0.00% | 0.00% | Jun 2026 |
| Integrated Wealth Concepts LLC | 13.00 | 0.00% | 0.00% | Jun 2026 |
| Hanson Mcclain Inc | 5.00 | 0.00% | -16.67% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 4.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 4.00 | 0.00% | 0.00% | Jun 2026 |
| Steward Partners Investment Advisory, LLC | 2.00 | 0.00% | +100.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 1.00 | 0.00% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
PAVmed Inc company profile
- Company name
- PAVmed Inc
- Ticker
- PAVM.US
- Exchange
- USA Stocks
- Listed since
- Apr 28, 2016
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 41
- Fiscal year end
- December
- Address
- 360 Madison Avenue, New York, NY, United States, 10017
- Phone
- 917 813 1828
- Website
- pavmed.com
About PAVmed Inc
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
PAVmed Inc management
10- Dr. Lishan Aklog M.D.Chairman & CEO · born 1966
- Mr. Dennis M. McGrath CPAPresident & CFO · born 1957
- Mr. Shaun M. O'Neill M.B.A.Executive VP & COO · born 1982
- Mr. Michael Adam GordonExecutive VP, General Counsel & Secretary · born 1975
- Dr. Brian J. deGuzman M.D.Executive VP, Chief Technology & Compliance Officer · born 1965
- Dr. Suman M. Verma M.D., Ph.D.Senior VP of Molecular Genetics & Chief Scientific Officer
- Mr. Matthew RileySenior Director of Investor Relations
- Dr. Deepika A. Lakhani Ph.D.Senior VP, Chief Regulatory & Quality Officer
- Dr. Victoria T. Lee M.D.Executive Vice President & Chief Medical Officer · born 1986
- Mr. Joseph VirgilioSVP & Chief Business Officer of Medical Devices · born 1975